Total Hip Replacement Study Of GSK576428 (Fondaparinux Sodium)

NCT00320398 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 114

Last updated 2018-09-04

Study results available
· View outcomes & findings →

Summary

This study is requested by PMDA to confirm the optimal dose for THR (total hip replacement).

Conditions

  • Thrombosis, Venous

Interventions

DRUG

Fondaparinux

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-01-30
Primary Completion
2006-07-18
Completion
2006-07-18

Countries

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00320398 on ClinicalTrials.gov